Alzheimer’s Drug

Alpha Cognition Launches Sales of Alzheimer’s Drug ZUNVEYL

by | Mar 18, 2025
"The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease," said Lauren D’Angelo, COO and chief commercial officer at Alpha Cognition. The drug is designed to provide "a differentiated treatment option" for patients with mild-to-moderate Alzheimer’s diagnoses.
MORE
Alpha Cognition Gets FDA Acceptance of New Alzheimer’s Drug Application
by | Dec 13, 2023
Based in Vancouver with a North Texas office in Frisco, Alpha Cognition said its novel oral tablet ALPHA-1062 is designed for the treatment of people with mild to moderate Alzheimer's disease. The company was honored at the recent BioNTX iC3 Summit as one of eight "Rising Stars."
MORE